Compound library / Healing & recovery / Immune Support

Thymosin Alpha-1

Naturally occurring thymic peptide explored for immune modulation and antiviral support via TLR activation on dendritic cells and T-cell maturation.

CategoryImmune Support
Regulatory standingNo approved product cited
Typical routeSubcutaneous
Half-life~2 hours
Common dose range1.6 mg 2x/week maintenance, up to 6.4 mg 2x/week acute
Typical cycle length4-8 weeks

BioHack Track models Thymosin Alpha-1 at a half-life of 2 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Reconstitute with bacteriostatic water.

Storage

Refrigerate after reconstitution.

Cautions

Approved in some countries for hepatitis/immune indications; not FDA-approved in the US.

Track Thymosin Alpha-1 in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Immune Support

What the evidence says

Evidence Check asks 10 questions about every compound. For Thymosin Alpha-1 it can answer 1 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.

Insufficient EvidenceLongevity

Only reviews or early work — not enough to say either way.

  • Aging and Thymosin Alpha-1Review · Int J Mol Sci · 2025 · PMID 41373628

Look up the research

These open a search of each database for Thymosin Alpha-1 — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Selected published studies

9 papers naming Thymosin Alpha-1 in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support